Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD

NCT ID: NCT02652598

Last Updated: 2017-01-19

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-11-30

Brief Summary

The experimental design is an open-label two-week trial of tolcapone to evaluate which clinical domains are affected by tolcapone treatment and to identify "responders" to tolcapone treatment in the two subject groups (BI and NCD)

Detailed Description

Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.

Clinical Instruments for patients:

• Question banks from large patient-reported outcome measure initiatives will be used and administered and used by computerized-adaptive tests (CATs). These include the TBI-QoL for patients with TBI and question banks from the patient-reported outcome measure information systems (PROMIS) and neurology quality of life measurement initiative (Neuro-QoL). Patients will answer questions related to their mobility, fatigue, pain interference, positive affect and well-being, depression, anxiety, anger and irritability, and emotional and behavioral dyscontrol.
• Clinical Global Impressions Scale
• Geriatric Depression Scale-15
• State-Trait Anxiety Inventory
• Hopkins Adult Reading Test
• Frontal Systems Behavior Scale
• Montreal Cognitive Assessment
• Trails A&B
• Modified Wisconsin Card Sorting Test
• NIH Toolbox
• Perceptual Comparison Test
• Brief Test of Attention
• Hopkins Verbal Learning Test
• Brief Visuospatial Memory Test
• Calibrated Ideational Fluency Assessment
• Profile of Mood States
• Digit Span

Clinical Instruments for Informants:

• Neuropsychiatry Inventory
• Apathy evaluation scale
• Overt aggression scale
• Frontal Systems Behavior Scale

Laboratory Measures:

• Blood sample for genotyping
• Blood sample for assessing COMT activity.
• Blood sample for a laboratory profile including CBC, CMP, TSH, Hepatitis Panel (B and C), and RPR
• A urine analysis, urine drug screen, and a urine pregnancy test
• In addition for NCD patients: a blood sample for tests including Serum Calcium, B12, ESR, and C-reactive protein

Conditions

Brain Injuries, Traumatic; Neurocognitive Disorders; Brain Injuries

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Open-Label

Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.

Group Type: EXPERIMENTAL

Tolcapone

Intervention Type: DRUG

Interventions

Tolcapone

Intervention Type: DRUG

Other Intervention Names

Tasmar

Eligibility Criteria

Inclusion Criteria

• Age 18-70
• Diagnosis of mild, moderate, or severe TBI, or history of ABI with classification to be made based on parameters at the time of the index event or acquired brain injury.
• Index event resulting in Traumatic or Acquired Head Injury occurred >12 months prior to trial initiation
• A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of TBI or ABI
• Proficient in the English language
• Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol
• Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the referring Sheppard Pratt physician.
• Stable medication dose and regimen for 2 months

• Age 60-75
• NCD diagnosed by a Sheppard Pratt physician, per DSM-5
• No abnormalities on other serum tests to rule out other cause of cognitive impairment: TSH, B12, CBC, Chemistry screen, and RPR.
• Recent structural neuroimaging (within 1 year or since the time of the onset of cognitive complaint)-noncontrast head CT or MRI-to rule out any gross lesion inconsistent with the diagnosis of MCI (e.g. subdural hematoma, normal pressure hydrocephalus, demyelinating lesion, infarct, or mass lesion)
• Proficient in the English language
• A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of NCD
• Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol
• Stable neurological and psychiatric symptomatology for 2 months prior to trial initiation as determined by the impression of the referring Sheppard Pratt physician.
• Stable medication dose and regimen for 2 months

Exclusion Criteria

• History of, or active, liver disease or abnormal liver function tests--if the patient currently has elevated Alanine Transaminase (ALT) or Aspartate Transaminase (AST) levels that exceed 2 times the upper limit of normal [Normal Reference Ranges ALT (Male: 4-40 IU/L, Female: 4-40 IU/L), AST (Male: 4-31 IU/L, Female: 4-37 IU/L) or the ratio of AST:ALT has exceeded 2:1
• Active alcohol use disorder, as defined by DSM-5, of any severity mild, moderate, or severe
• History of, or active, cardiovascular disease defined as: coronary heart disease, manifested by myocardial infarction, angina pectoris, or heart failure
• Uncontrolled hypo-or hypertension based on Joint National Committee criteria (JNC7) Hypotension: Systolic<90mmHg or diastolic<60mmHg Hypertension: Systolic >140mmHg or diastolic>90 mmHg)
• History of extra-pyramidal symptoms (e.g. tardive dyskinesia, neuroleptic malignant syndrome, or QT prolongation) while on a first-generation anti-psychotic
• Active illicit substance use, resulting in a substance use disorder as defined by DSM-5, of any severity mild, moderate, or severe
• Patient is currently taking tolcapone or any of the following medications that can interact with tolcapone resulting in an adverse events: another COMT inhibitor, benserazide, α-methyldopa, dobutamine, apomorphine, isoproterenol, clozapine, MAO inhibitor
• Known allergy or serious adverse reaction to tolcapone
• Participated in any investigational drug trial in the past 30 days.
• Pregnant or planning to become pregnant during the study period
• Breastfeeding or planning to breastfeed during the study period.

• Presence of pre-morbid/pre-TBI cognitive impairment or behavioral dysfunction, as per informant or medical documentation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Lieber Institute for Brain Development (LIBD)

UNKNOWN

Sponsor Role: collaborator

Sheppard Pratt Health System

OTHER

Sponsor Role: lead

Responsible Party

Robert Schloesser, MD

Executive Director of Sheppard Pratt-Lieber Research Institute, Inc.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Robert J Schloesser, MD

Role: PRINCIPAL_INVESTIGATOR

Sheppard Pratt Health System

Locations

Sheppard Pratt Health System

Baltimore, Maryland, United States

Countries

United States

Other Identifiers

805704

Identifier Type: -

Identifier Source: org_study_id